123 related articles for article (PubMed ID: 17250585)
1. The retrocyclin analogue RC-101 prevents human immunodeficiency virus type 1 infection of a model human cervicovaginal tissue construct.
Cole AL; Herasimtschuk A; Gupta P; Waring AJ; Lehrer RI; Cole AM
Immunology; 2007 May; 121(1):140-5. PubMed ID: 17250585
[TBL] [Abstract][Full Text] [Related]
2. The formulated microbicide RC-101 was safe and antivirally active following intravaginal application in pigtailed macaques.
Cole AM; Patton DL; Rohan LC; Cole AL; Cosgrove-Sweeney Y; Rogers NA; Ratner D; Sassi AB; Lackman-Smith C; Tarwater P; Ramratnam B; Ruchala P; Lehrer RI; Waring AJ; Gupta P
PLoS One; 2010 Nov; 5(11):e15111. PubMed ID: 21124745
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of lime juice as a topical microbicide candidate.
Fletcher PS; Harman SJ; Boothe AR; Doncel GF; Shattock RJ
Retrovirology; 2008 Jan; 5():3. PubMed ID: 18190686
[TBL] [Abstract][Full Text] [Related]
4. RC-101, a retrocyclin-1 analogue with enhanced activity against primary HIV type 1 isolates.
Owen SM; Rudolph DL; Wang W; Cole AM; Waring AJ; Lal RB; Lehrer RI
AIDS Res Hum Retroviruses; 2004 Nov; 20(11):1157-65. PubMed ID: 15588337
[TBL] [Abstract][Full Text] [Related]
5. Peptide-derivatized SB105-A10 dendrimer inhibits the infectivity of R5 and X4 HIV-1 strains in primary PBMCs and cervicovaginal histocultures.
Bon I; Lembo D; Rusnati M; Clò A; Morini S; Miserocchi A; Bugatti A; Grigolon S; Musumeci G; Landolfo S; Re MC; Gibellini D
PLoS One; 2013; 8(10):e76482. PubMed ID: 24116111
[TBL] [Abstract][Full Text] [Related]
6. Preclinical evaluation of synthetic -2 RANTES as a candidate vaginal microbicide to target CCR5.
Kish-Catalone TM; Lu W; Gallo RC; DeVico AL
Antimicrob Agents Chemother; 2006 Apr; 50(4):1497-509. PubMed ID: 16569870
[TBL] [Abstract][Full Text] [Related]
7. Retrocyclin RC-101 blocks HIV-1 transmission across cervical mucosa in an organ culture.
Gupta P; Ratner D; Ding M; Patterson B; Rohan LC; Reinhart TA; Ayyavoo V; Huang X; Patton DL; Ramratnam B; Cole AM
J Acquir Immune Defic Syndr; 2012 Aug; 60(5):455-61. PubMed ID: 22592582
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial polypeptides are key anti-HIV-1 effector molecules of cervicovaginal host defense.
Cole AM; Cole AL
Am J Reprod Immunol; 2008 Jan; 59(1):27-34. PubMed ID: 18154593
[TBL] [Abstract][Full Text] [Related]
9. Vaginal gel formulation based on theaflavin derivatives as a microbicide to prevent HIV sexual transmission.
Yang J; Li L; Jin H; Tan S; Qiu J; Yang L; Ding Y; Jiang ZH; Jiang S; Liu S
AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1498-508. PubMed ID: 22867271
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of -2 RANTES vaginal microbicide formulations in a nonhuman primate simian/human immunodeficiency virus (SHIV) challenge model.
Kish-Catalone T; Pal R; Parrish J; Rose N; Hocker L; Hudacik L; Reitz M; Gallo R; Devico A
AIDS Res Hum Retroviruses; 2007 Jan; 23(1):33-42. PubMed ID: 17263630
[TBL] [Abstract][Full Text] [Related]
11. A theta-defensin composed exclusively of D-amino acids is active against HIV-1.
Owen SM; Rudolph D; Wang W; Cole AM; Sherman MA; Waring AJ; Lehrer RI; Lal RB
J Pept Res; 2004 Jun; 63(6):469-76. PubMed ID: 15175019
[TBL] [Abstract][Full Text] [Related]
12. The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission.
Fichorova RN; Tucker LD; Anderson DJ
J Infect Dis; 2001 Aug; 184(4):418-28. PubMed ID: 11471099
[TBL] [Abstract][Full Text] [Related]
13. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion.
Veazey RS; Klasse PJ; Schader SM; Hu Q; Ketas TJ; Lu M; Marx PA; Dufour J; Colonno RJ; Shattock RJ; Springer MS; Moore JP
Nature; 2005 Nov; 438(7064):99-102. PubMed ID: 16258536
[TBL] [Abstract][Full Text] [Related]
14. Anti-HIV-1 Activity of Lactic Acid in Human Cervicovaginal Fluid.
Tyssen D; Wang YY; Hayward JA; Agius PA; DeLong K; Aldunate M; Ravel J; Moench TR; Cone RA; Tachedjian G
mSphere; 2018 Jul; 3(4):. PubMed ID: 29976641
[TBL] [Abstract][Full Text] [Related]
15. Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models.
Tsai CC; Emau P; Jiang Y; Agy MB; Shattock RJ; Schmidt A; Morton WR; Gustafson KR; Boyd MR
AIDS Res Hum Retroviruses; 2004 Jan; 20(1):11-8. PubMed ID: 15000694
[TBL] [Abstract][Full Text] [Related]
16. Assessment of cervicovaginal cytokine levels following exposure to microbicide Nisin gel in rabbits.
Aranha CC; Gupta SM; Reddy KV
Cytokine; 2008 Jul; 43(1):63-70. PubMed ID: 18513989
[TBL] [Abstract][Full Text] [Related]
17. Retrocyclin-2: structural analysis of a potent anti-HIV theta-defensin.
Daly NL; Chen YK; Rosengren KJ; Marx UC; Phillips ML; Waring AJ; Wang W; Lehrer RI; Craik DJ
Biochemistry; 2007 Sep; 46(35):9920-8. PubMed ID: 17685559
[TBL] [Abstract][Full Text] [Related]
18. Development and evaluation of a thermoreversible ovule formulation of stampidine, a novel nonspermicidal broad-spectrum anti-human immunodeficiency virus microbicide.
D'Cruz OJ; Samuel P; Waurzyniak B; Uckun FM
Biol Reprod; 2003 Dec; 69(6):1843-51. PubMed ID: 12890726
[TBL] [Abstract][Full Text] [Related]
19. Antiviral activity of retrocyclin RC-101, a candidate microbicide against cell-associated HIV-1.
Gupta P; Lackman-Smith C; Snyder B; Ratner D; Rohan LC; Patton D; Ramratnam B; Cole AM
AIDS Res Hum Retroviruses; 2013 Feb; 29(2):391-6. PubMed ID: 22924614
[TBL] [Abstract][Full Text] [Related]
20. The anti-HIV microbicide candidate RC-101 inhibits pathogenic vaginal bacteria without harming endogenous flora or mucosa.
Eade CR; Cole AL; Diaz C; Rohan LC; Parniak MA; Marx P; Tarwater PM; Gupta P; Cole AM
Am J Reprod Immunol; 2013 Feb; 69(2):150-8. PubMed ID: 23167830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
